MSF frequently publishes updates, press releases, and other forms of communication about its work in roughly 70 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

Country/Region

Topic

January 20, 2015

Doctors Without Borders/Médecins Sans Frontières (MSF) today called on pharmaceutical companies GlaxoSmithKline (GSK) and Pfizer to slash the price of the pneumococcal vaccine to US$5 per child in developing countries, ahead of a major vaccination donor conference in Berlin.

January 16, 2015

Vaccination is a cornerstone of Doctors Without Borders/Médecins Sans Frontières’ (MSF) work to reduce illness and death caused by preventable diseases. While global immunization coverage reached 84 percent in 2013, in some places vaccination rates have stagnated, leaving behind children chronically unimmunized and unprotected. For more than 40 years, MSF has been at the forefront of vaccine delivery in crisis contexts, and in response to outbreaks of vaccine-preventable diseases. We also conduct routine immunization in areas where health systems have failed.

January 16, 2015

Up to 20,000 people in the southern tip of Malawi, the area most affected by current flooding, remain cut off from the rest of the country without food, health care, or means to prevent possible disease outbreaks.

January 15, 2015

Doctors Without Borders/Médecins Sans Frontières (MSF) clinical psychologist Hélène Thomas carried out two assignments in Central African Republic (CAR) between April and December 2014 and opened MSF’s program of medical and psychological support for victims of sexual violence (VSV) at the general hospital in Bangui, CAR’s capital.

Again and again, she heard the testimonies of people imprisoned by violence and trauma.

January 15, 2015

Thousands of IDPs seeking refuge in the Kurdistan Regional Government of Iraq have now settled in Dohuk governorate, where four MSF teams are providing care for the most vulnerable people.

January 14, 2015

The Indian Patent Controller today rejected one of Gilead’s key patent applications, which covered the drug sofosbuvir, used to treat hepatitis C (HCV). The oral drug, which first received regulatory approval in the US in November 2013, and has been priced by Gilead at US$84,000 for a treatment course, or $1,000 per pill in the US, has caused a worldwide debate on the pricing of patented medicines. A study from Liverpool University showed that sofosbuvir could be produced for as little as $101 for a three-month treatment course.

January 13, 2015

More than one in four babies in Pakistan is born with a low birth weight, and malnutrition largely contributes to a high mortality rate among young children. In Balochistan Province, Doctors Without Borders/Médecins Sans Frontières (MSF) provides medical assistance to mothers and babies in Dera Murad Jamali. Since it opened in 2010, nearly 40,000 children have been treated in MSF’s program.

January 12, 2015

In the wake of a major attack carried out by the Islamist militant group Boko Haram on the northern Nigerian town of Baga, a Doctors Without Borders/Médecins Sans Frontières (MSF) team is assisting survivors who fled to the city of Maiduguri. A large number of people are believed to have been slaughtered in the attack—the deadliest by Boko Haram for five years—while thousands more were displaced from their homes.

Twenty wounded survivors are being treated in Maiduguri hospital by Ministry of Health teams.

January 08, 2015

By Aitor Zabalgogeazkoa, Head of Mission of the MSF team in Aleppo in 2014

In 2013, the outlook in Syria was bleak. But the reality is that everything can get worse.

January 08, 2015

Five years have passed since a devastating earthquake shook Haiti, affecting approximately 3 million people and killing 220,000, according to government estimates. What is the situation in Haiti now after five years of reconstruction efforts, and what health care services does Doctors Without Borders/Médecins Sans Frontières (MSF) still provide in the country? MSF’s Haiti Country Director Oliver Schulz discusses:

Pages